Zivo Bioscience Inc (ZIVO)

[premiumjavacoffee]

From Red Chip Newsletter: ZIVO Completes Pilot Study with Promising Results that Address $3 Billion Unmet Market Need
http://www.redchip.com/news/article/19
In early January, ZIVO Biosciences (OTCQB: ZIVO) announced the successful completion of its pilot study with one of the world’s largest animal health companies. The study tested a solution to the inflammatory condition known as bovine mastitis, which costs the US dairy industry an estimated $3 billion per year. Globally, this condition is considered the number one health problem affecting the world’s 244 million dairy cows.

Results from the study indicate that seven of nine dairy cows in a tested group showed normal milk appearance after eight days of product administration, while seven of eight infected dairy cows with no product administered were unable to produce milk to be tested.

Preliminary bacterial culture results indicate that the number and viability of mycoplasma organisms in the udders of treated cows are noticeably decreased when compared to an untreated control group infected with the same pathogen. Researchers postulate that the Company’s product supports the animal’s immune response to the infection.

“This is very good news for us,” states chief medical officer Dr. Scott Freeman. “We had anticipated improvements in milk quality and udder appearance, but to actually see an effect on the viability of the pathogen itself is very promising, given the fact that there are no approved options available to dairy producers today.”

Dr. Amy Steffek, director of research and development added, “For the dairy producer, this could mean dairy cows can be put back into production much sooner than is the current practice.”

In a parallel development, the Company is exploring several near-term applications, where the original natural biomass is minimally processed, relying primarily on its signature lipids and peptides to offer a natural nutritive profile. In so doing, management is opening talks with potential production partners.

“We’re primarily an R&D entity,” states Andrew Dahl, President and CEO. “Even though we’ve developed the scale-up protocols and pilot production capability with the Arizona Center for Algae Technology and Innovation, we’re looking to partner with an established commercial producer to deliver natural biomass in large quantities and in compliance with regulations regarding animal feed ingredients.”

Beyond the blockbuster potential of its animal health products, ZIVO is also addressing another sizeable market opportunity: human wellness.

Wellness testing is the latest countermeasure taken by insurers, employers and governments to keep a lid on exploding healthcare costs. By screening individuals for metabolic efficiency and overall health, those responsible for paying or administering health-related claims get a better handle on risk management and intervention.

Trion Solutions, a leading human resources firm with over 1,000 clients and 15,000 employees, recognizes the importance of screening and recently committed to a pilot program to evaluate the health and economic benefits offered by ZIVO subsidiary WellMetris’ proprietary Wellness Profile testing platform.

The pilot program with Trion will start with 500 employees. Based on attainment of the price/performance metrics projected by WellMetris, Trion Solutions plans to underwrite a program to test a much larger group of eligible individuals and dependents.

Craig A. Vanderburg, Chief Operating Officer of Trion Solutions, stated, "We are excited about using the WellMetris test to establish a baseline of health for our employees. It's a potential breakthrough that can provide valuable information to the individuals who take the test and the wellness consultants or early intervention providers tasked with improving employee health."

The company’s proprietary health and wellness test assesses metabolic status to help focus early intervention and preventative medicine, driving ROI for employers, insurers, and governments. The test is designed to uncover pre-conditions favorable to the onset of disease or impairment usually brought on by unhealthy or stressful lifestyle choices, focusing primarily on the "The Big Four" -- stroke, heart disease, diabetes and cancer.

The WellMetris test is a breakthrough product, converting expensive lab tests for stress and inflammation into a simple, convenient test that can be performed at the office, on the shop floor or in a retail setting, as well as at clinics and health centers. No other company offers an easy-to-use, cost-effective, and portable wellness test system.

ZIVO is yet another example of the great small-cap opportunities we find for you as a member of the RedChip Nation. With two potential blockbuster products addressing $1+ billion market opportunities, we believe ZIVO represents an extremely compelling story with big upside in the near-term.

Visit RedChip.com to learn more about this exciting small-cap stock, and be sure to watch our latest interview with CEO Andrew Dahl. You can also sign up for to receive email alerts and our upcoming research profile on ZIVO.